Rhabdomyosarcoma: new windows of opportunity
Philip P Breitfeld1, William H Meyer
1Duke University Medical Center, Durham, North Carolina, USA.
Abstract:
Rhabdomyosarcoma is a highly malignant, small blue cell tumor characterized by muscle differentiation. With modern treatment, more than 70% of children and adolescents with this disease are cured. Adequate biopsy to obtain sufficient tissue for accurate diagnosis and molecular characterization is critical. Patients must be assessed for tumor extent; the Intergroup Rhabdomyosarcoma Study (IRS) clinical group and Staging system is universally applied in North America. Multidisciplinary therapy is necessary to maximize cure rates. Local control relies on complete surgical excision when possible; those whose tumors are not completely excised and those with alveolar histology tumors require local irradiation to maximize local control. In North America, vincristine (Oncovin); Eli Lilly and Company, Indianapolis, http://www.lilly.com), dactinomycin (Cosmegen); Merck & Co., Inc., Whitehouse Station, NJ, http://www.merck.com), and cyclophosphamide are the standard chemotherapy agents. The IRS has used therapeutic window studies to confirm the predictive nature of preclinical xenograft models and to identify several new single agents and combinations of agents with activity in high-risk patient groups. Despite these efforts, the outcome for these high-risk patients remains poor. The next generation of Children's Oncology Group studies will evaluate the efficacy of topoisomerase-I inhibitors and dose-compression therapy approaches. New advances in molecular characterization of tumors, including gene-expression analysis, may identify new therapeutic targets that can be exploited by expanded preclinical drug discovery efforts, and hold the promise of revolutionizing risk-based therapies.
Insights
Rhabdomyosarcoma, a rare childhood cancer, shows over 70% cure rates with modern multidisciplinary therapy. Ongoing research explores new agents and molecular targets to improve outcomes for high-risk patients.
Area of Science:
- Pediatric Oncology
- Cancer Research
- Tumor Biology
Background:
- Rhabdomyosarcoma is a malignant small blue cell tumor with muscle differentiation.
- Current treatments achieve over 70% cure rates in children and adolescents.
- Accurate diagnosis and staging are crucial for effective management.
Purpose of the Study:
- To outline current diagnostic and therapeutic strategies for rhabdomyosarcoma.
- To highlight the importance of multidisciplinary care and staging systems like the Intergroup Rhabdomyosarcoma Study (IRS).
- To discuss ongoing research and future directions in treating high-risk rhabdomyosarcoma.
Main Methods:
- Application of the IRS clinical group and Staging system for patient assessment.
- Multidisciplinary therapy including surgical excision and local irradiation.
- Standard chemotherapy regimens (vincristine, dactinomycin, cyclophosphamide) and therapeutic window studies.
Main Results:
- Multidisciplinary therapy and standard chemotherapy have improved cure rates.
- Therapeutic window studies have identified active agents in high-risk groups.
- Despite progress, outcomes for high-risk rhabdomyosarcoma patients remain challenging.
Conclusions:
- Complete surgical excision and local irradiation are key for local control.
- Newer approaches like topoisomerase-I inhibitors and dose-compression therapy are under investigation.
- Molecular characterization holds promise for identifying novel therapeutic targets and revolutionizing risk-based therapies.
